Hims & Hers Health is set to acquire European telehealth platform Zava, aiming to expand its services across Europe. The deal promises to add 1.3 million customers and enhance access to affordable medications in Ireland, France, and Germany.
The FDA has approved the Teal Wand, the first at-home alternative to Pap smears, offering a painless and convenient way for women to screen for cervical cancer. With the aim of increasing screening rates, this innovative device allows women to collect samples at home and mail them for lab testing.
A new study reveals a significant rise in American adults seeking talk therapy, with more individuals opting for psychotherapy over psychiatric medications. This trend marks a shift in mental health treatment, driven by increased access and awareness.
Novo Nordisk is partnering with telehealth providers Hims & Hers, Ro, and Life MD to make its weight loss drug Wegovy more accessible. Shares soar as Wegovy becomes readily available.
Hims & Hers Health shares skyrocketed nearly 30% in premarket trading following a groundbreaking partnership with Novo Nordisk to sell the weight loss drug Wegovy. Discover what this means for investors!
